Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holding Company (NASDAQ:SCLX) is a pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio is intended to address conditions that may otherwise require opioid-based therapies, with an emphasis on prescription medicines and locally or systemically delivered treatments.

Scilex’s commercial products include ZTlido, a prescription lidocaine topical system approved for the treatment of pain associated with postherpetic neuralgia; ELYXYB, an oral solution of celecoxib indicated for the acute treatment of migraine with or without aura in adults; and Gloperba, an oral liquid formulation of colchicine used to treat and prevent gout flares. The company has also pursued investigational therapies for pain and related conditions, including treatments designed for epidural or localized administration.

Scilex was established as a subsidiary of Sorrento Therapeutics and became a publicly traded company through a business combination with Vickers Vantage Corp. I in 2022. The company is based in San Diego, California, and primarily serves the U.S. prescription pharmaceutical market. Jaisim Shah has served as Scilex’s chief executive officer and has been involved in the company’s corporate and commercial development.

Key Stats

• Today's Range: $1.40 to $1.57
• 50-Day Range: $1.56 to $5.41
• 52-Week Range: $1.40 to $27.00
• Volume: 48,586 shs
• Average Volume: 74,376 shs
• Market Capitalization: $12.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 21% of companies evaluated by MarketBeat, and ranked 819th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Scilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Scilex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.63% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 3.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently decreased by 10.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Scilex has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Scilex this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Scilex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.50% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/13/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCLX
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($49.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$358.73 million
• Net Margins: -1,414.57%
• Pretax Margin: -1,469.71%
• Return on Equity: N/A
• Return on Assets: -147.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $30.25 million
• Price / Sales: 0.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($24.94) per share
• Price / Book: -0.06

Miscellaneous

• Outstanding Shares: 8,490,000
• Free Float: 8,111,000
• Market Cap: $12.23 million
• Optionable: No Data
• Beta: 1.85